Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Outcome of Children Previously Treated with rhIGF-1/rhIGFBP-3 for Prevention of Retinopathy of Prematurity
2014-003556-31Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of Premiplex in retinopathy of prematurity (ROP) (2 arms), sponsored by Takeda. Primary endpoint: Long-term safety and outcome after rhIGF-1/rhIGFBP-3 exposure. Started Dec 2014; status: completed.
02
Drugs
Premiplex
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2014-003556-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003556-31.